MedTrace Logo

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

NCT04334057 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2025-08-29

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and effectiveness of Esperoct® for long-term routine use in patients with Haemophilia A. Participants will get Esperoct® as prescribed by their doctor. The study will last for about 2 years for each participant.

Conditions

  • Haemophilia A

Interventions

DRUG

Turoctocog alfa pegol

Patients will be treated with commercially available Esperoct® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.

Sponsors & Collaborators

Principal Investigators

  • Clinical Reporting Anchor & Disclosure (1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2023-11-30
Completion
2024-01-10

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04334057 on ClinicalTrials.gov